Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002646 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT00002646 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 1,500 participants.
The verdict
NCT00002646, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining chemotherapy with hormone therapy may kill more tumor cells. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide may be an effective way to prevent the recurrence of breast cancer. It is not yet known whether tamoxifen plus fenretinide is more effective than tamoxifen alone for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen plus fenretinide with tamoxifen alone in treating postmenopausal women who have stage II or stage III breast cancer that is estrogen receptor positive and/or progesterone receptor positive.
Interventions
- DRUG tamoxifen citrate
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 1995-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002646
The ClinicalTrials.gov registry entry for NCT00002646 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tamoxifen citrate is the first listed.
NCT00002646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002646 about?
NCT00002646 is a clinical study titled "Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining chemotherapy with hormone therapy may kill more tumor cells. Chemoprevention therapy is the use of certain drugs to try to preven...
What is the current status of trial NCT00002646?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 1995-10.
What interventions are being tested in trial NCT00002646?
The interventions under investigation include: tamoxifen citrate (DRUG), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00002646?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.